GEN and GNMSF Related Headlines

Go Back

GEN and GNMSF Related Press Releases

Go Back

Jun 23, 2016 10:33AM Genmab Provides Update on Marketing Authorization Application for Arzerra(r) (ofatumumab) as Maintenance Therapy for Patients with Relapsed CLL
Jun 2, 2016 01:49AM Genmab Announces Phase III Studies of Ofatumumab in Relapsing Multiple Sclerosis
May 30, 2016 10:59AM Genmab Achieves USD 30 Million Milestone in DARZALEX(r) (daratumumab) Collaboration with Janssen
May 23, 2016 07:15AM Genmab Announces European Conditional Marketing Authorization for DARZALEX(r) (daratumumab) for Multiple Myeloma
May 18, 2016 01:28PM Genmab Announces Positive Topline Result in Phase III POLLUX Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
May 17, 2016 04:03PM Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL accepted for priority review by FDA
May 10, 2016 11:15AM Genmab Announces Financial Results for the First Quarter of 2016
Apr 20, 2016 10:53AM Genmab Announces Daratumumab Data to be Presented at 2016 ASCO Annual Meeting
Apr 20, 2016 01:08AM Genmab Updates Financial Guidance for 2016
Apr 4, 2016 02:10PM Patent Infringement Lawsuit Filed Against Genmab and Janssen in the United States Regarding DARZALEX(r)
Apr 1, 2016 11:46AM CHMP Issues Positive Opinion Recommending DARZALEX(r) (daratumumab) for Relapsed and Refractory Multiple Myeloma
Mar 30, 2016 12:19PM Genmab Announces Positive Interim Result in Phase III Castor Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
Mar 21, 2016 01:22PM Genmab Announces Studies of Daratumumab in Combination with Atezolizumab in a Solid Tumor and Multiple Myeloma
Mar 17, 2016 01:54PM Constitution of the Board of Directors in Genmab A/S and Grant of Warrants to Employees in Genmab
Mar 10, 2016 03:01PM Genmab Announces Submission of Supplemental Biologics License Application to FDA for Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL
Mar 9, 2016 02:21PM Genmab Achieves Second Milestone in Daratumumab NHL Study Under Collaboration with Janssen
Mar 9, 2016 11:03AM Genmab Announces European Regulatory Submission for Ofatumumab in Combination with Fludarabine and Cyclophosphamide for Relapsed CLL
Mar 8, 2016 02:16AM Genmab Provides Update on Ofatumumab Development in Autoimmune Indications
Feb 17, 2016 11:10AM Genmab 2015 Annual Report
Feb 4, 2016 06:32PM Major Shareholder Announcement
Jan 19, 2016 03:25PM Genmab Announces U.S. FDA Approval of Arzerra(r) (ofatumumab) as Extended Treatment for Recurrent or Progressive CLL
Dec 21, 2015 12:08PM Genmab Achieves $3 Million Milestone in DuoBody Platform Collaboration with Janssen
Dec 18, 2015 09:08AM Genmab Achieves $3 Million Milestone for Progress in DuoBody Platform Collaboration with Janssen
Dec 9, 2015 09:56AM Genmab Achieves USD 5 Million Milestone in Daratumumab Collaboration with Janssen
Nov 23, 2015 05:08PM Genmab Announces Ofatumumab Phase III Study in Follicular Lymphoma to be Stopped Following Planned Interim Analysis
Nov 19, 2015 06:14PM Genmab Achieves USD 45 Million Milestone in DARZALEX(TM) (daratumumab) Collaboration With Janssen
Nov 17, 2015 11:38AM Major Shareholder Announcement
Nov 16, 2015 02:29PM Genmab Announces U.S. FDA Approval of DARZALEX(TM) (daratumumab) for Multiple Myeloma and Updates Financial Guidance
Nov 3, 2015 11:09AM Genmab Announces Financial Results for the First Nine Months of 2015 and Improves 2015 Financial Guidance
Oct 25, 2015 05:44PM Genmab Achieves $3 Million Milestone Payment in DuoBody Platform Collaboration with Janssen
Oct 23, 2015 09:36AM Major shareholder announcement for Genmab A/S
Oct 16, 2015 10:19AM Major Shareholder Announcement
Oct 8, 2015 12:01PM Major Shareholder Announcement
Oct 5, 2015 09:51AM Genmab Reaches $3 Million Milestone Payment in DuoBody Platform Collaboration with Janssen
Sep 29, 2015 11:38AM Major Shareholder Announcement
Sep 25, 2015 05:14AM CHMP Grants Accelerated Assessment for Daratumumab for Double Refractory Multiple Myeloma
Sep 19, 2015 09:49AM U.S. FDA Grants Priority Review for Ofatumumab as Maintenance Therapy for Relapsed CLL
Sep 9, 2015 07:38AM Genmab Announces European Regulatory Submission for Daratumumab in Double Refractory Multiple Myeloma
Sep 4, 2015 02:25PM U.S. FDA Grants Priority Review for Daratumumab for Double Refractory Multiple Myeloma
Sep 2, 2015 04:14PM Major Shareholder Announcement
Aug 27, 2015 01:35AM Data Published in The New England Journal of Medicine Shows Daratumumab Monotherapy Induced Durable Responses in Heavily Pre-treated Relapsed or Refractory Multiple Myeloma Patients
Aug 14, 2015 06:37AM Genmab Enters Commercial License Agreement with Novo Nordisk for DuoBody Technology
Aug 12, 2015 01:59AM Genmab Announces Financial Results for the First Half of 2015
Jul 22, 2015 08:27AM Genmab Announces Submission of Supplemental Biologics License Application to FDA for Ofatumumab as Maintenance Therapy for Relapsed CLL
Jul 10, 2015 11:54AM Major Shareholder Announcement for Genmab A/S
Jul 9, 2015 01:53PM Genmab Announces Completion of Rolling Submission of Biologics License Application for Daratumumab in Multiple Myeloma and Achievement of a USD 15 Million Milestone
Jul 7, 2015 07:40AM Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL

GEN and GNMSF Related SEC Filings

Go Back